Free Trial
NASDAQ:GNFT

GENFIT (GNFT) Stock Price, News & Analysis

GENFIT logo
$3.82 -0.12 (-2.93%)
As of 08/1/2025 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About GENFIT Stock (NASDAQ:GNFT)

Key Stats

Today's Range
$3.67
$3.90
50-Day Range
$3.61
$4.51
52-Week Range
$2.55
$6.42
Volume
2,836 shs
Average Volume
2,969 shs
Market Capitalization
$190.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Buy

Company Overview

GENFIT Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

GNFT MarketRank™: 

GENFIT scored higher than 34% of companies evaluated by MarketBeat, and ranked 742nd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GENFIT has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    GENFIT has received no research coverage in the past 90 days.

  • Read more about GENFIT's stock forecast and price target.
  • Earnings Growth

    Earnings for GENFIT are expected to decrease in the coming year, from $0.95 to ($0.57) per share.

  • Price to Book Value per Share Ratio

    GENFIT has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.07% of the float of GENFIT has been sold short.
  • Short Interest Ratio / Days to Cover

    GENFIT has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in GENFIT has recently decreased by 1.14%, indicating that investor sentiment is improving.
  • Dividend Yield

    GENFIT does not currently pay a dividend.

  • Dividend Growth

    GENFIT does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.07% of the float of GENFIT has been sold short.
  • Short Interest Ratio / Days to Cover

    GENFIT has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in GENFIT has recently decreased by 1.14%, indicating that investor sentiment is improving.
  • News Sentiment

    GENFIT has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for GENFIT this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, GENFIT insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.20% of the stock of GENFIT is held by insiders.

  • Percentage Held by Institutions

    Only 2.24% of the stock of GENFIT is held by institutions.

  • Read more about GENFIT's insider trading history.
Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GENFIT and its competitors with MarketBeat's FREE daily newsletter.

GNFT Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Headlines

GNFT Stock Analysis - Frequently Asked Questions

GENFIT's stock was trading at $3.71 at the start of the year. Since then, GNFT shares have increased by 2.8% and is now trading at $3.8150.

GENFIT (GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GENFIT investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), NVIDIA (NVDA), Occidental Petroleum (OXY), Vaxart (VXRT), American Airlines Group (AAL) and Carnival (CCL).

Company Calendar

Today
8/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GNFT
CIK
1757064
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$13.00
Potential Upside/Downside
+240.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.08
Current Ratio
1.23
Quick Ratio
1.23

Sales & Book Value

Annual Sales
$76.77 million
Price / Sales
2.48
Cash Flow
$0.07 per share
Price / Cash Flow
54.33
Book Value
$1.50 per share
Price / Book
2.54

Miscellaneous

Outstanding Shares
50,000,000
Free Float
47,903,000
Market Cap
$190.75 million
Optionable
Not Optionable
Beta
1.14

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:GNFT) was last updated on 8/4/2025 by MarketBeat.com Staff
From Our Partners